Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Subscribe To Our Newsletter & Stay Updated
